The perception of Jazz Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary ...

Share price of JAZZ Pharmaceuticals JAZZ hit $102.82 on Tuesday, close to its 52-week low of $99.06. This decline is ...

Learn more about whether Intra-Cellular Therapies, Inc. or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ ...

Learn more about whether Jazz Pharmaceuticals plc or Zoetis Inc. is a better investment based on AAII's A+ Investor grades, ...

Sei Investments Co. decreased its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 30.5% in the 4th quarter, ...

Teacher Retirement System of Texas boosted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

At Jazz Pharmaceuticals, Gaslightwala oversaw a portfolio of products with annual sales of $1B, including ZIIHERA®, ZEPZELCA®, and RYLAZE®. AKTX-101 is Akari's lead candidate targeting the ...

These brands include ZIIHERA ® for HER2+ cancers, ZEPZELCA ® for small cell lung cancer, and RYLAZE ®, DEFITELIO ®, and VYXEOS ® for a range of hematological malignancies. As previously announced, Mr.

BOSTON and LONDON, March 20, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biotechnology company developing next-generation precision bi ...